Pharmaxis Ltd · Frenchs Forest, New South Wales Australia (Australian: PXS)
| 10 Rodborough Rd., Unit 2 | Phone: +61-2-9454-7200 |
| Frenchs Forest, New South Wales | Fax: +61-2-9451-3622 |
| 2086 | |
| Australia | 
Map This Company |
Pharmaxis Ltd Rankings
Company Description
Pharmaxis has an ax to grind with chronic respiratory and autoimmune diseases. The Australian company researches, develops, and markets therapeutic pharmaceutical products to combat these and other illnesses. Pharmaxis has received approval to market asthma treatment Aridol in select regions. The company has research and development programs for additional disease targets such as cystic fibrosis, chronic obstructive pulmonary disease, bronchiectasis, and pulmonary fibrosis. Pharmaxis acquired respiratory therapeutics developer TOPIGEN Pharmaceuticals in 2010, adding to Pharmaxis' roster of potential treatments for respiratory disorders including asthma and COPD.
Pharmaxis Ltd Reports
No subscription, no problem.
Download presentation-ready reports. From company profiles to the competitive landscape, Hoover's offers immediate access to individual reports.
Financials
| Company Type | Public - Australian: PXS Headquarters |
|---|---|
| Fiscal Year-End | June |
| Employees | 70 |
Executives
8 executives listed for Pharmaxis Ltd's Frenchs Forest, New South Wales location.
| Chairman | Denis Hanley | |
|---|---|---|
| CEO and Managing Director | Alan Robertson | |
| COO | John Crapper |